

# An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology

Joseph J Gingell<sup>1,2</sup>, John Simms<sup>3</sup>, James Barwell<sup>3</sup>, David R Poyner<sup>3</sup>, Harriet A Watkins<sup>1,2</sup>, Augen A Pioszak<sup>4</sup>, Patrick M Sexton<sup>5</sup>, Debbie L Hay<sup>1,2</sup>

<sup>1</sup>*School of Biological Sciences, University of Auckland, Auckland, New Zealand;* <sup>2</sup>*Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand;* <sup>3</sup>*School of Life and Health Sciences, Aston University, Birmingham, UK;* <sup>4</sup>*Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA;* <sup>5</sup>*Drug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia*

*Cell Discovery* (2016) 2, 16020; doi:10.1038/celldisc.2016.20; published online 21 June 2016

---

**Correction to:** *Cell Discovery* (2016) 2, 16012; doi:10.1038/celldisc.2016.12; published online 17 May 2016

During web production, there was an error in Supplementary information: Supplementary Material was omitted. The files are now installed in the online version of the paper.

We apologize for any inconvenience that may have been caused by this error.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>